BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company focused on developing novel antibacterial products for serious infections caused by multi-drug resistant (MDR) bacteria, announced that its management will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is scheduled for September 14-16, 2026, in New York City.
The company's Chief Financial Officer, Hernan Levett, will deliver the live presentation on September 16, 2026, from 12:30 PM to 1:00 PM ET at the Lotte New York Palace, Kennedy II (4th Floor). Additionally, a pre-recorded on-demand presentation by CEO Dr. Marc Gitzinger will be available starting September 11, 2026, at 7:00 AM ET, with a 90-day replay. The webcast will be accessible on the H.C. Wainwright platform or on the BioVersys website in the investor section.
This announcement comes as BioVersys advances its pipeline targeting some of the most intractable health threats: antibiotic-resistant bacteria. The World Health Organization has identified antimicrobial resistance as one of the top global public health and development threats, projecting that drug-resistant infections could cause 10 million deaths per year by 2050. BioVersys aims to address this crisis through its two internal technology platforms: TRIC (Transcriptional Regulator Inhibitor Compounds) and Ansamycin Chemistry. These platforms are designed to overcome resistance mechanisms, block virulence production, and directly affect bacterial pathogenesis, potentially offering new treatment options in the antimicrobial and microbiome fields.
The company's lead programs target Acinetobacter baumannii, a notorious hospital-acquired pathogen, and tuberculosis. Their most advanced candidate, BV100, is in Phase 3 clinical trials for nosocomial infections caused by Acinetobacter baumannii. Another program, alpibectir, is in Phase 2 for tuberculosis, developed in collaboration with GlaxoSmithKline (GSK) and a consortium including the University of Lille, France. These efforts highlight BioVersys's commitment to addressing high unmet medical needs in life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders.
The presentation at the H.C. Wainwright conference provides an opportunity for investors and industry leaders to gain insights into BioVersys's strategy and progress. The company's participation underscores the growing interest in innovative approaches to combat antimicrobial resistance. For leaders in business and technology, this news is significant as it reflects the intersection of biotech innovation and global health challenges, with potential implications for healthcare systems and economies worldwide. The development of effective antibacterial treatments could reduce healthcare costs, improve patient outcomes, and mitigate the burden of resistant infections on society.
BioVersys is headquartered in Basel, Switzerland, a major biotech hub. Investors and interested parties can request one-on-one meetings with the company's CEO and CFO during the conference by contacting their H.C. Wainwright representative.
